Therapeutic compounds

Patent metadata

Field	Value
Publication number	US-10005741-B2
Application number	US-201815873704-A
Country	US
Kind code	B2
Filing date	Jan 17, 2018
Priority date	Feb 26, 2014
Publication date	Jun 26, 2018
Grant date	Jun 26, 2018

Abstract

The invention provides compounds and compositions that are useful for treating conditions including Alzheimer's disease, Parkinson's disease, diabetes, cancer, and psychotic disorders such as schizophrenia.

First claim

What is claimed is:

1. A method for treating disease in an animal comprising administering a compound of formulae II to the animal, wherein the compound of formulae II is:

where:
X is N, Y is CH and Z is N;
X is N, Y is CH and Z is CH;
X is N, Y is N and Z is CH;
X is CH, Y is CH and Z is CH;
R 2 is H or methyl; and
R 3 is ethyl that is optionally substituted with one or more groups independently selected from F, Cl, and Br; wherein the ring containing X, Y, and Z is optionally substituted on carbon with one or more groups independently selected from halo;
or a pharmaceutically acceptable salt thereof;
provided the compound is not:

wherein the disease is Alzheimer's disease, Parkinson's disease, diabetes, cancer, or a psychotic disorder.

2. The method of claim 1 wherein the compound of formulae II is selected from formula IIa, IIb, and IIc:

wherein:
R 2 is H or methyl; and
R 3 is ethyl that is optionally substituted with one or more groups independently selected from F, Cl, and Br;
or a pharmaceutically acceptable salt thereof.

3. The method of claim 1 wherein the compound of formulae II is selected from formulae IIc:

wherein:
R 2 is H or methyl; and
R 3 is ethyl that is optionally substituted with one or more groups independently selected from F, Cl, and Br;
or a pharmaceutically acceptable salt thereof.

4. The method of claim 1 wherein the compound of formulae II is selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

5. The method of claim 1 wherein the compound of formulae II is selected from formulae IIa and IIc:

wherein:
R 2 is H or methyl; and
R 3 is ethyl that is optionally substituted with one or more groups independently selected from F, Cl, and Br;
or a pharmaceutically acceptable salt thereof.

6. The method of claim 1 wherein the compound of formulae II is

or a pharmaceutically acceptable salt thereof.

7. The method of claim 1 wherein the compound of formulae II is selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

8. The method of claim 1 wherein the compound of formulae II is selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

9. A method for treating disease in an animal comprising administering a compound to the animal, wherein the compound is selected from the group consisting of:

or a pharmaceutically acceptable salt thereof;
wherein the disease is Alzheimer's disease, Parkinson's disease, diabetes, cancer, or a psychotic disorder.

Assignees

• Univ Arizona State

Inventors

• Wagner Carl
• Marshall Pamela
• Jurutka Peter

Classifications

• C07D235/10

  Radicals substituted by halogen atoms or nitro radicals · CPC title

• C07D239/42

  One nitrogen atom (nitro radicals C07D239/30) · CPC title

• C07D249/18 Primary

  Benzotriazoles · CPC title

• C07D333/54

  with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring · CPC title

• C07D213/79

  Acids; Esters · CPC title